Actualités en direct des projets (non traduites)
Nouvelles en VO
PrimeGrid - Pi Approximation Day Challenge starts July 22
- Détails
Source
World Community Grid - July 2022 Tech Team Update
- Détails
Source
Yafu - Aliquot sequence 22^67 has terminated!!!
- Détails
Source
Rosetta@home - COVID-19 vaccine with IPD nanoparticles wins full approval abroad
- Détails
The IPD is excited to announce it's first designed protein medicine with full approval abroad.
Congrats and thank you to all Rosetta@home contributors! The computing you have provided has greatly aided in de novo protein design challenges such as vaccine development leading to breakthroughs like this.
For more information you can visit the IPD vaccine news post.
A video is also available here.
From the IPD news site:
• Clinical testing found the vaccine outperforms Oxford/AstraZeneca’s
• The protein-based vaccine, now called SKYCovione, does not require deep freezing
• University of Washington to waive royalty fees for the duration of the pandemic
• South Korea to purchase 10 million doses for domestic use
A vaccine for COVID-19 developed at the University of Washington School of Medicine has been approved by the Korean Ministry of Food and Drug Safety for use in individuals 18 years of age and older. The vaccine, now known as SKYCovione, was found to be more effective than the Oxford/AstraZeneca vaccine sold under the brand names Covishield and Vaxzevria.
SK bioscience, the company leading the SKYCovione’s clinical development abroad, is now seeking approval for its use in the United Kingdom and beyond. If approved by the World Health Organization, the vaccine will be made available through COVAX, an international effort to equitably distribute COVID-19 vaccines around the world. In addition, the South Korean government has agreed to purchase 10 million doses for domestic use.
The Seattle scientists behind the new vaccine sought to create a ‘second-generation’ COVID-19 vaccine that is safe, effective at low doses, simple to manufacture, and stable without deep freezing. These attributes could enable vaccination at a global scale by reaching people in areas where medical, transportation, and storage resources are limited.
“We know more than two billion people worldwide have not received a single dose of vaccine,†said David Veesler, associate professor of biochemistry at UW School of Medicine and co-developer of the vaccine. “If our vaccine is distributed through COVAX, it will allow it to reach people who need access.â€
The University of Washington is licensing the vaccine technology royalty-free for the duration of the pandemic.
Congrats and thank you again to all R@h contributors!
Source
NumberFields@home - New badge type
- Détails
I already put the hooks in to keep tract of the field counts for sf7. Now it's just a matter of creating the badge images, etc. Hopefully that should be done in the next several days.
Happy crunching!
Source
SRBase - llr 64bit apps update soon
- Détails
Source
- SRBase - SRBase 32bit apps - end of life
- World Community Grid - OPN1 Project Update
- SRBase - base R2 2nd conjecture / 2 Megaprimes
- World Community Grid - Website and Forum Restart!
- Wanless Mersenne +2 - 12-digit factor of P2203 has now been found by the project...
- PrimeGrid - M.C. Escher's Birthday Challenge starts June 17th